Back to top

Analyst Blog

Recently, Covidien plc.’s (COV - Analyst Report) electroencephalography (EEG)-based monitors, especially the Bispectral Index ("BIS") monitor, was recommended by UK-based National Institute for Health and Clinical Excellence ("NICE"). These devices belong to the company’s Respiratory and Monitoring Solutions product line, and are used to measure the level of anesthesia during surgeries.

The NICE Diagnostics Guidance is supported by reliable clinical proofs and a report by the University of Southampton’s Southampton Health Technology Assessment Centre. Several medical device manufacturers and healthcare institutes also recommended Covidien’s monitors.

The guidance is specifically intended for patients with high risk of deep anesthesia or unintended awareness. Further, the device can be used during general surgeries as well as for patients receiving total intravenous anesthesia.

The recommendation from the prestigious NICE organization should further boost customer confidence in Covidien’s innovative and cost-effective product line. It will benefit the company’s Oximetry and Monitoring business under the core Medical Devices division to expand in U.K. However, the product line faces tough competition such as the E-Entropy and Schiller Narcotrend-Compact M brain monitoring technologies developed by GE Healthcare, a unit under General Electric Company (GE - Analyst Report).

The BIS Brain Function Monitoring Systems are capable of measuring the exact level of consciousness in patients and hence allows anesthetists to provide precise dosage of drugs to suit individual patient’s requirement. This reduces potential risks and enhances patient’s comfort. Some of BIS System’s featured products are the BIS Complete 2-Channel Monitor, the BIS Complete 4-Channel Monitor and the BIS Unilateral Sensors.

With a market-cap of $27.18 billion, Covidien is a leading global health care products company with an impressive history of developing and manufacturing high-quality products in a cost-effective manner. The company boasts a well diversified product and technology portfolio.

However, Covidien faces stiff competition and remains exposed to pricing, utilization headwinds, along with acquisition risks. We remain concerned about the tepid health services industry amid a soft European economy. Also, foreign exchange translation is expected to dampen sales growth.

We currently have a long-term Neutral recommendation on the stock, which carries a short-term Zacks #3 Rank (Hold).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%
NUSTAR GP H… NSH 41.14 +2.59%